Prometrium

Basic Prometrium Information

• INN (International Nonproprietary Name): Progesterone.
• Brand Names Available In Australia: Prometrium (capsules 100 mg, 200 mg).
• ATC Code: G03DA04.
• Forms & Dosages: Soft capsules 100 mg and 200 mg in blister packs (30/90); vaginal softgels/capsules 100 mg and 200 mg in boxes of 15/30.
• Manufacturers In Australia: AbbVie (manufacturer of Prometrium); other international suppliers include Besins Healthcare (Utrogestan) and generics from companies such as Teva and Mylan.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Findings

Patients and prescribers ask whether new studies change how micronised progesterone is used in HRT and menstrual disorders.

European and Austrian clinical work from 2022 to 2025 has concentrated on micronised progesterone formulations, most commonly oral soft‑gel capsules sold as Prometrium or Utrogestan.

Meta‑analyses and multicentre EU trials in that period confirm that micronised progesterone (INN: progesterone; ATC G03DA04) reliably protects the endometrium when given with oestrogen in sequential HRT regimens.

Trials also reinforce the licensed regimen to induce withdrawal bleeding for secondary amenorrhoea, with the commonly used dosing of 400 mg once nightly for 10 days producing predictable bleeding in most patients.

Safety monitoring in these studies emphasised standard contraindications: severe hepatic dysfunction, current or past hormone‑sensitive cancers, and a history of thrombosis.

Practical warnings in the literature and product labelling note excipients such as peanut oil in some formulations and the need to check packaging where peanut allergy is a concern.

The following compact table summarises key trial endpoints reported in recent European and Austrian work (2022–2025).

Overall, the most robust and consistent data for micronised progesterone support licensed regimens and the drug’s role in HRT and menstrual management.

Clinical Effectiveness In Austria

People often want to know whether results from large trials match real practice in Austria.

Prescription data from Austrian Sozialversicherung flows and E‑Medikation/e‑card records show micronised progesterone is mainly prescribed for endometrial protection during HRT and for secondary amenorrhoea.

Local hospital gynaecology units report outcomes that mirror EU trial findings when licensed doses are used.

National pharmacovigilance recorded by the Österreichische Apothekerkammer and spontaneous adverse‑event reports follow the EU safety profile, so monitoring liver function during long‑term therapy and evaluating thrombotic risk factors before starting therapy remain routine.

• Measured Outcome — Withdrawal Bleeding Rates: Most patients treated with 400 mg nightly for 10 days achieved withdrawal bleeding within the expected interval.
• Measured Outcome — Patient‑Reported Side Effects: Headache, breast tenderness and drowsiness were the most frequent mild side effects reported in outpatient datasets.
• Measured Outcome — Discontinuation Rates: Discontinuations were generally low when counselling about expected bleeding patterns and side effects was provided.

Practical note for prescribers and pharmacists: prescriptions are rezeptpflichtig (prescription only) and are transmitted through the E‑Medikation/e‑card system in outpatient care.

Indications And Extended Uses

Patients ask which uses are licensed and which are common in practice but off‑label.

Licensed indications across EMA/FDA product information include endometrial protection during postmenopausal oestrogen therapy and treatment of secondary amenorrhoea using the product‑label dosages.

Common regimens used in Austria follow the licence: 200 mg nightly for 12 days of a 28‑day cycle for HRT endometrial protection, and 400 mg nightly for 10 days to induce withdrawal bleeding for secondary amenorrhoea.

Off‑label but frequent regional practices include vaginal administration of oral softgels for local luteal support or recurrent miscarriage protocols; this is referenced in parts of Europe and Asia but is not uniformly licensed.

All off‑label use should be documented in the E‑Medikation and discussed with the patient, including the evidence level and implications for reimbursement.

• Licensed Indications: Endometrial protection with oestrogen in sequential HRT; induction of withdrawal bleeding in secondary amenorrhoea.
• Common Off‑Label Uses: Vaginal insertion of oral softgels for local luteal support; recurrent miscarriage protocols in selected clinics (practice varies by country).

Composition And Brand Overview

People commonly ask how Prometrium and Utrogestan differ and what is in the capsule.

The active ingredient is micronised progesterone (INN: progesterone) in soft‑gel capsule form, typically available as 100 mg and 200 mg strengths.

Brand names encountered in Austria and nearby EU markets include Prometrium (AbbVie) and Utrogestan (Besins), both supplied as soft capsules in pack sizes such as 15, 30 or 90 units depending on market packaging.

Note on excipients: some formulations use peanut oil as the capsule vehicle, and packaging in some jurisdictions must warn about peanut allergy.

ATC classification for micronised progesterone is G03DA04.

In Austria, pharmacies including larger chains and independent Apotheken dispense prescription products, and registration and marketing authorisations are recorded in national databases.

Contraindications And Special Precautions

Patients want to know when progesterone must not be used and what to check before dispensing.

Absolute contraindications from product information and EU labelling include severe hepatic dysfunction, known or suspected breast cancer or other hormone‑dependent malignancy, undiagnosed abnormal vaginal bleeding, current or past thrombosis (DVT, PE, stroke, MI), allergy to peanut oil where present, and pregnancy warnings where applicable.

Relative precautions requiring close monitoring include active liver disease, migraine with aura, certain psychiatric disorders, asthma and established cardiovascular disease.

• Contraindications: Severe hepatic dysfunction; known or suspected hormone‑dependent cancer; current or history of thrombosis; undiagnosed vaginal bleeding; allergy to peanut oil (if present).
• Relative Precautions: Mild/moderate hepatic or renal impairment; migraine; depression/psychiatric history; asthma; cardiovascular disease.

Pharmacy screening checklist before supply:

• Confirm prescription and indication via the E‑Medikation.
• Check for liver disease and recent liver function tests if on long‑term therapy.
• Ask about personal or family history of thrombosis or breast cancer.
• Confirm any allergies, specifically peanut allergy when packaging/leaflet indicates peanut oil.
• Document findings in the e‑prescription record and alert the prescriber if concerns exist.

Dosage Guidelines

One of the most common questions at the counter is, “What dose should I take and when?”

Licensed dosing examples from product information are straightforward and form the backbone of clinical use.

Available capsule strengths are 100 mg and 200 mg, so prescribers commonly instruct two 200 mg capsules or dose combinations to reach prescribed totals.

Dose adjustments and cautions:

• Contraindicated in severe hepatic impairment; avoid dosing adjustments in this group.
• Use caution and monitor elderly patients for increased sensitivity.
• Renal impairment data are limited; prescribe with caution and clinical monitoring.

Missed dose advice: take as soon as remembered unless it is near the next scheduled dose; do not double up.

Overdose recommendations: supportive care; symptoms may include nausea, vomiting, withdrawal bleeding and sedation—seek medical advice promptly.

Overview Of Interactions

People often worry about interactions with other medicines, alcohol and supplements.

Micronised progesterone has fewer strong pharmacokinetic interactions than many synthetic progestins, but certain interactions remain clinically relevant.

The product information and clinical practice note additive CNS depression with alcohol and sedative medicines, and there is potential for altered metabolism with potent hepatic enzyme inducers or inhibitors.

Pharmacists in Austria rely on E‑Medikation interaction checks, which flag combination risks at dispensing.

Quick pharmacist checklist for interaction screening:

• Check E‑Medikation and software interaction alerts before supply.
• Ask the patient about alcohol and concurrent use of sedatives or hypnotics.
• Review current medicines for potent hepatic enzyme inducers/inhibitors and discuss monitoring if present.

Also review overlapping hormonal therapies such as combined systemic contraceptives or interacting HRT agents and liaise with the prescriber if changes are needed.

Cultural Considerations And Patient Behaviour

Patients often ask whether availability, cost or local beliefs will affect their choice of progesterone product.

Austrian patients show variation in access depending on urban versus rural location.

Urban centres have easier access to gynaecology specialists and larger pharmacy chains such as BENU, while rural patients may rely on independent Apotheken or consider cross‑border shopping into Germany, Czechia or Hungary for price differences.

The E‑card e‑prescription and Sozialversicherung system shape adherence and continuity, and many patients expect prescriptions to be handled through E‑Medikation.

Local patient groups and health forums often express a preference for “body‑identical” or “natural” progesterone over synthetic progestins, and this drives demand for micronised products such as Prometrium or Utrogestan.

• Access Modes: Retail Apotheken, hospital pharmacies, online pharmacy ordering with e‑prescription verification.
• Reimbursement Touchpoints: Sozialversicherung reimbursement varies by indication; HRT indications may receive partial coverage while off‑label uses often do not.
• Cultural Preference: Many patients request “micronised” or body‑identical progesterone for HRT.

Pharmacy counselling tips for rural or cross‑border patients include confirming prescription validity, advising on reimbursement documentation, and checking pack labelling for excipient warnings before travelling.

Availability And Price Overview

Customers ask where they can get Prometrium and whether Sozialversicherung will cover it.

Prometrium and Utrogestan (100 mg and 200 mg) are registered as prescription‑only products in most jurisdictions and are dispensed through hospital supply chains and retail Apotheken in Austria.

Distribution channels include retail pharmacies (chain and independent), hospital pharmacies and licensed online pharmacies that verify e‑prescriptions.

Price regulation and Sozialversicherung reimbursement depend on indication and national listings, and coverage may be partial for HRT while off‑label uses are less likely to be reimbursed.

Cross‑border purchasing remains a practice for some patients seeking price savings, but prescription validity and product registration must be checked before importation.

In our online pharmacy, prometrium is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences

Many patients ask whether a synthetic progestin is an acceptable substitute and why one product might be chosen over another.

Common alternatives available in Austria include synthetic progestins such as medroxyprogesterone acetate (Provera/generics) and dydrogesterone (Duphaston).

Differences to note:

• Medroxyprogesterone acetate: synthetic progestin; tablet and injectable forms; may have different metabolic and bleeding profiles compared with micronised progesterone.
• Dydrogesterone: oral synthetic progestogen with distinct structure and dosing patterns compared with micronised progesterone.
• Micronised progesterone: body‑identical progesterone, often preferred by patients for perceived physiological similarity and for HRT endometrial protection.

Frequently Asked Questions

These are the typical questions seen at pharmacy counters in Austria.

1. Can I use oral Prometrium vaginally?

   Some European clinics do use oral softgels vaginally off‑label for local luteal support.

   Discuss this with the prescriber and ensure the use is recorded in the E‑Medikation since licensing and evidence vary between countries.

2. Is it reimbursed by Sozialversicherung?

   Reimbursement depends on the indication and national formularies.

   HRT indications may attract partial reimbursement; check the e‑prescription reimbursement code for details.

3. I’m allergic to peanuts — can I take Prometrium?

   Some formulations contain peanut oil; always check the packaging and leaflet.

   If peanut oil is present, seek an alternative generic or formulation that does not contain peanut excipients.

4. Can I drive while taking progesterone?

   Drowsiness and sedation can occur, particularly at higher doses or in overdose situations.

   Advise patients to be cautious with driving or operating machinery until they know how the medicine affects them.

For pharmacy staff templates and counselling prompts, refer to Österreichische Apothekerkammer patient counselling materials for standard wording and documentation.

Guidelines For Correct Use (Pharmacy Counselling)

Patients frequently want a simple checklist to follow when starting progesterone.

Follow Österreichische Apothekerkammer standards when counselling and document advice in the E‑Medikation.

Essential counselling checklist for dispensing staff:

• Confirm the indication on the prescription and verify the e‑prescription/Rezeptpflicht status.
• Review absolute contraindications: severe hepatic disease, thrombotic history, hormone‑dependent cancer, undiagnosed bleeding, peanut allergy if applicable.
• Explain the dosing schedule clearly: for HRT endometrial protection, 200 mg nightly for 12 days of a 28‑day cycle; for secondary amenorrhoea, 400 mg nightly for 10 days.
• Missed dose advice: take as soon as remembered unless near the next dose; do not double up.
• Storage instructions: store below 25°C and protect from moisture and light; keep in original packaging.
• Side‑effect recognition: advise patients to seek immediate care for severe headache, sudden unilateral leg pain/swelling, shortness of breath, jaundice or severe chest pain.
• Document counselling interaction in E‑Medikation and notify the prescriber if any red flags are identified.

Short patient handout template (one line per key point):

• Take the capsules at bedtime as prescribed.
• Expect possible breast tenderness, headaches or mild bloating; these usually settle.
• If you have any symptoms of blood clots, severe liver issues or suspect pregnancy, stop and seek urgent care.
• Store below 25°C and return unused medicines to the pharmacy for safe disposal.

Delivery Across Australia

Final Notes For Pharmacists

Micronised progesterone is a well‑established option for endometrial protection and secondary amenorrhoea when used at licensed doses.

Keep clear records in E‑Medikation for any off‑label administration and ensure all contraindications and allergies are checked at dispensing.

Inform patients about expected side effects and safety signs that require urgent attention.

When in doubt, liaise with the prescriber, document advice, and use national guidance from the Österreichische Apothekerkammer for counselling templates and recordkeeping.

Patients asking about alternatives should be counselled on differences between body‑identical micronised progesterone and synthetic progestins, including differences in formulation, side‑effect profile and reimbursement implications.